Holen Sie sich die Stockscreener-App
26.73
1.00%
-0.27
Vorhandelsmarkt:
26.99
0.26
+0.97%
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
ArriVent BioPharma Shares Edge Lower Amid Sector CautionKAMA Signal - Newser
Cantor Fitzgerald reiterates Overweight rating on ArriVent stock By Investing.com - Investing.com Canada
(AVBP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Wall Street analysts think ArriVent BioPharma, Inc. (AVBP) could surge 72.44%: Read this before placing a bet - MSN
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo
ArriVent delays Phase 3 trial to mid-2026 but extends cash runway to Q4 2027, reducing funding risk. - Pluang
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case - Seeking Alpha
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $43 - Moomoo
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $50 - Moomoo
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50 - Moomoo
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from Oppenheimer - The Globe and Mail
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained - TipRanks
ArriVent BioPharma Releases Q1 2026 Financial Results - AlphaStreet
Arrivent BioPharma files prospectus supplement for $250 million at-the-market offering By Investing.com - Investing.com Australia
ArriVent BioPharma Updates At-The-Market Equity Offering Program - TipRanks
Arrivent Biopharma Enters Open Market Sale Agreement For Offer And Sell Common Stock Up To $250 MillionSEC Filing - TradingView
Arrivent BioPharma files prospectus supplement for $250 million at-the-market offering - Investing.com UK
ArriVent BioPharma (AVBP) files $250M ATM program with Jefferies - Stock Titan
ArriVent BioPharma (NASDAQ: AVBP) adds $250M ATM stock flexibility - Stock Titan
ArriVent BioPharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ArriVent BioPharma Reports First Quarter 2026 Financial Results - The Manila Times
ArriVent BioPharma (NASDAQ: AVBP) posts Q1 2026 loss and details oncology pipeline progress - Stock Titan
ArriVent (Nasdaq: AVBP) Q1 2026 loss narrows while pivotal cancer trials progress - Stock Titan
ArriVent Phase 3 and Phase 1 cancer trials backed by $326M through 2027 - Stock Titan
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate - Yahoo Finance
ArriVent BioPharma Inc expected to post a loss of 89 cents a shareEarnings Preview - TradingView
Arrivent’s MUC16/NaPi2b-targeted ADC gains IND clearance - BioWorld News
FDA clears new dual-target cancer drug for ovarian, endometrial trial - Stock Titan
Liquidity Mapping Around (AVBP) Price Events - Stock Traders Daily
FMR LLC (AVBP) discloses 3.02M shares, 6.8% stake in Arrivent Biopharma - Stock Titan
$207B Market Shift: The Race for Fast Track Approval in Oncology - Quantisnow
FY2026 Earnings Estimate for AVBP Issued By Lifesci Capital - MarketBeat
ArriVent BioPharma: A First Assessment (NASDAQ:AVBP) - Seeking Alpha
[ARS] ArriVent BioPharma, Inc. SEC Filing - Stock Titan
ArriVent BioPharma (NASDAQ: AVBP) details 2026 virtual meeting, board elections and CEO pay - Stock Titan
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained - TipRanks
Why (AVBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Are you looking for a top momentum pick? Why ArriVent BioPharma, Inc. (AVBP) is a great choice - MSN
Citigroup Increases ArriVent BioPharma (NASDAQ:AVBP) Price Target to $45.00 - MarketBeat
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45 - Moomoo
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cantor Fitzgerald initiates coverage of ArriVent BioPharma (AVBP) with overweight recommendation - MSN
Are medical stocks lagging ArriVent BioPharma, Inc. (AVBP) this year? - MSN
ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month HighWhat's Next? - MarketBeat
Vicor, AXT And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Stocks generating improved relative strength: ArriVent BioPharma - MSN
What macro factors move ArriVent (AVBP) stock most (Stalls) 2026-04-18Community Risk Signals - Xã Vĩnh Công
Arrivent Biopharma stock hits 52-week high at $29.56 By Investing.com - Investing.com Australia
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):